Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Synonyms||Lisocabtagene maraleucel|JCAR 017|
JCAR017 (lisocabtagene maraleucel) comprises equal amount of CD4+ and CD8+ autologous T lymphocytes engineered to express chimeric antigen receptors containing an anti-CD19 fragment fused to the 4-1BB (CD137) signaling domain, which may results in immune modulating and anti-tumor activities (J Clin Oncol 35, 2017 (suppl; abstr 7513)).
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Cyclophosphamide + Fludarabine + JCAR017||Cyclophosphamide Fludarabine JCAR017||0||1|
|Durvalumab + JCAR017||Durvalumab JCAR017||0||1|
|Ibrutinib + JCAR017||Ibrutinib JCAR017||0||1|